Skip to main content

Table 1 Low-density Lipoprotein Cholesterol (LDL-C) and Non-HDL-C Goals for Patients in Different CVD Risk Categories from the Adult Treatment Panel III of the National Cholesterol Education Program [12, 30]

From: Treatment of dyslipidemia in patients with type 2 diabetes

Risk Category Goals (mg/dL)
  Primary target: LDL-C Secondary target: Non-HDL-C
CVD + T2DM (CVD risk equivalent)* < 70 < 100
CVD or T2DM < 100 < 130
≥ 2 risk factors (not CVD risk equivalents) < 130 < 160
0-1 risk factor (not a CVD risk equivalent) < 160 < 190
  1. CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; T2DM, type 2 diabetes mellitus; non-HDL-C = LDL-C + very-low-density lipoprotein cholesterol (VLDL-C) or total cholesterol - HDL-C.
  2. *In addition to reduction of LDL-C to a goal of < 70 mg/dL as an option in very high-risk patients with overt CVD (level of evidence B), additional American Diabetes Association (ADA) recommendations are the reduction of LDL-C by 30%-40% in all patients with diabetes and overt CVD, regardless of baseline LDL-C levels (level of evidence A); lower triglycerides to < 150 mg/dL and raise HDL-C to > 40 mg/dL, with the option of > 50 mg/dL in women (level of evidence C) [10].
  3. In addition to the reduction of LDL-C to < 100 mg/dL as the primary therapeutic goal (level of evidence A), the ADA recommends that LDL-C be reduced by 30%-40% in all patients with diabetes > 40 years of age without overt CVD, regardless of baseline LDL-C levels (level of evidence C) [10].
  4. ‡Non-HDL-C is a secondary target of therapy in patients with high serum triglycerides (≥ 200 mg/dL) [30].